Introduction: What they say:
A study from Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California 94305, USA; Paul F. Glenn Center for the Biology of Aging, Stanford University School of Medicine, Stanford, California 94305, USA Neuroscience Graduate Program, Stanford University School of Medicine, Stanford, California 94305, USA; Center for Tissue Regeneration, Repair and Restoration, V.A. Palo Alto Healthcare System, Palo Alto, California 94304, USA shows that “Human umbilical cord plasma proteins revitalize hippocampal function in aged mice.“ This research paper was published, in the 19 April 2017 issue of the journal “Nature” [One of the best research journals in General sciences with an I.F of 43+], by Prof. Wyss-Coray, Castellano JM and others.
What we say:
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Ribonucleic acid-based therapy for enhancing memory and cognition: LncRNA PVT1 increases Tissue inhibitor of metalloproteinases 2 (TIMP2) levels, improves cognition, and decreases age-associated decline in memory and learning, via down-regulation of its target genes
What is known?
Prof.Tony Wyss-Coray’s research team has recently shown that: (1) human cord plasma treatment promotes cognitive and learning function in aged mice; (2) blood-borne component Tissue inhibitor of metalloproteinases 2 (TIMP2) is enriched in human cord plasma, young mouse plasma, and young mouse hippocampi; (3) TIMP2 increases hippocampal-dependent cognition; and (4) treating brain slices with TIMP2 antibody inhibits long-term potentiation and prevents hippocampal function, suggesting that increasing the expression of TIMP2 in aged individuals may enhance learning and memory.
From Research findings to Therapeutic opportunity:
This study suggests, for the first time, LncRNA PVT1 (long noncoding RNA plasmacytoma variant translocation 1 gene) may aid in the improvement of learning, memory, and cognition. LncRNA PVT1, by increasing the expression of its target genes, may increase the levels of TIMP2. Thereby, it may: (1) increase the expression of genes that promote learning and memory; (2) cognition and learning; (3) improve spatial memory; and (4) promote hippocampal function (fig.1).
Thus, pharmacological formulations encompassing “LncRNA PVT1 or its activators, either alone or in combination with other drugs,“ may be used to suppress the age-associated overall physiological decline of hippocampal function and improve cognition and memory (fig.2).
Details of the research findings:
Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Undisclosed mechanistic information: How does LncRNA PVT1 increase the levels of TIMP2?
For purchase and payment details, you may reach us at email@example.com
# Research cooperation
Web: http://genomediscovery.org or http://newbioideas.com
Citation: Boominathan, L., Ribonucleic acid-based therapy for enhancing memory and cognition: LncRNA PVT1 increases Tissue inhibitor of metalloproteinases 2 (TIMP2) levels, improves cognition, and decreases age-associated decline in memory and learning, via down-regulation of its target genes, 12/March/2019, 9.18 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite, drop us a line at firstname.lastname@example.org